EXHIBIT 99.1

Appendix 4C

Quarter Ended 30 September 2015

San Diego, California and Sydney, Australia (Friday, 30 October 2015, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 September 2015. The Appendix 4C is unaudited.

Third Quarter Highlights

Effective 23 September 2015, the Company welcomed its incoming Chief Executive Officer, Regina Groves. With an extensive background in coronary medical devices and executive management, most recently at Medtronic, Inc., she is positioning the Company for commercialization of its Fantom^® scaffold, a next generation drug-eluting bioresorbable coronary scaffold. Robert Stockman, REVA’s former CEO, remains non-executive Chairman of the Board.

During the third quarter of 2015, the Company’s operating activities focused on the clinical study of Fantom. After initiating the study in March 2015, the Company announced enrollment of 110 patients on 30 September 2015. Data from these patients will be gathered and assessed during the first half of 2016 and is planned to be used in a CE Mark application that is targeted for the third quarter of 2016. If approved, the CE Mark would allow REVA to sell in Europe and other countries that recognize the CE Mark. Fantom utilizes REVA’s advanced proprietary polymer that allows for thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

Following the successful enrollment of the first 110 patients, the Company continued enrolling patients, with the goal to enroll a total of 220 patients in the study. Data from the additional patients will be used for commercialization purposes.

Also during the third quarter, the Company collected and analyzed six-month results from the initial patients implanted with Fantom in December 2014. These results, showing effective scaffold function and good vessel patency, were presented at a major industry conference the week of 12 October 2015.

While supporting the clinical enrollments during the quarter, the Company’s technical team continued their work on the proprietary polymer and certain other scaffold components to support the scale-up of manufacturing occurring through commercialization. They also continued to evaluate additional product opportunities within the Company’s intellectual property portfolio. If viable opportunities are identified, an assessment of development approaches and resource needs will be made before progressing with product development.

Following the conclusion of the third quarter, on 1 October 2015, the Company received US$9,506,000 cash proceeds from the issuance of 4,375,000 shares of common stock upon the exercise of warrants. The warrants had been issued under the convertible note financing on 14 November 2014. With these warrant proceeds, the Company believes it has adequate cash and

__________________________________________________________________________________________

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111   •   +1 (858) 966-3000   •   +1 (858) 966-3099 (FAX)   •   www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000   •   +61 2 9237 2800

ARBN 146 505 777   •   REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

REVA Medical, Inc. – ASX AnnouncementPage 2

investments to fund its operating and capital needs into, and possibly through, the third fiscal quarter of 2016. Following this exercise, a total of 4,375,000 warrants remain outstanding with an exercise value of US$11,407,000.

Appendix 4C

As of 30 September 2015, the Company’s cash balance was US$11,845,000 and its interest-bearing investments were US$497,000 for a total of US$12,342,000. The current quarter end cash balance reflects a decrease of US$4,036,000 from the 30 June 2015 quarter end balance of US$15,881,000, primarily as a result of expenditures related to normal operating activities and capital equipment purchases of US$246,000.

The Company plans to file its Form 10-Q Quarterly Report (the “Quarterly Report”) with the U.S. Securities and Exchange Commission and with the Australian Securities Exchange on or about 10 November 2015. The Quarterly Report provides financial statements, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the quarter ended 30 September 2015.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom^® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on 30 March  2015, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

_________________________________________________________________________________________

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111   •   +1 (858) 966-3000   •   +1 (858) 966-3099 (FAX)   •   www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000   •   +61 2 9237 2800

ARBN 146 505 777   •   REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/03/00  Amended 30/09/01, 24/10/05, 17/12/10

Consolidated statement of cash flows

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 1

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 2

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

Financing facilities available

Add notes as necessary for an understanding of the position.

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 3

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Reconciliation of cash

Acquisitions and disposals of business entities

Compliance statement

Sign here:  ../s/ Katrina L. Thompson................Date:  30 October 2015

(Chief Financial Officer/Company Secretary)

Print name:  Katrina L. Thompson

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 4

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Notes

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 5